Moderna, Inc.宣布,其研究性肿瘤靶向癌症抗原疗法在针对实体瘤的一期临床试验中,已为首例患者完成给药。该试验旨在评估该疗法的安全性与初步疗效。
Moderna, Inc.宣布,其研究性肿瘤靶向癌症抗原疗法在针对实体瘤的一期临床试验中,已为首例患者完成给药。该试验旨在评估该疗法的安全性与初步疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.